HIV infection and pulmonary arterial hypertension

References

• Petrosillo N. Pulmonary vascular disease and infection: a tale of two diseases. Clin. Microbiol. Infect. DOI: 10.1111/j.1469–0691.2010.03291.x (2010) (Epub ahead of print).
   Google Scholar
• Opravil M, Pechère M, Speich R et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am. J. Respir. Crit. Care Med.155, 990–995 (1997).
   PubMed Web of Science ®Google Scholar
• Hsue PY, Deeks SG, Farah HH et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS22(7), 825–833 (2008).
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaout A et al. Pulmonary arterial hypertension in France. Am. J. Respir. Crit. Care Med.173, 1023–1030 (2006).
   PubMed Web of Science ®Google Scholar
• Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest100, 1268–1271 (1991).
   PubMed Web of Science ®Google Scholar
• Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS22, 35–40 (2008).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Lascoux-Combe C, Delfraissy JF et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am. J. Respir. Crit. Care Med.177, 108–113 (2008).
   PubMed Web of Science ®Google Scholar
• Zuber JP, Calmy A, Evison JM et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin. Infect. Dis.38, 1178–1185 (2004).
   PubMed Web of Science ®Google Scholar
• Cicalini S, Chinello P, Cicini MP, Petrosillo N. Pulmonary arterial hypertension and HIV infection. AIDS22, 2219–2220 (2008).
   PubMed Web of Science ®Google Scholar
• Himelman RB, Dohrmann M, Goodman P et al. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am. J. Cardiol.64, 1396–1399 (1989).
   PubMed Web of Science ®Google Scholar
• Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest118, 1133–1141 (2000).
   PubMed Web of Science ®Google Scholar
• Nunes H, Humbert M, Sitbon O et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.167, 1433–1439 (2003).
   PubMed Web of Science ®Google Scholar
• Degano B, Guillaume M, Savale L et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS24, 67–75 (2010).
   PubMed Web of Science ®Google Scholar
• Petitpretz P, Brenot F, Azarian R et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation89, 2722–2777 (1994).
   PubMed Web of Science ®Google Scholar
• Pellicelli AM, Palmieri F, Cicalini S, Petrosillo N. Pathogenesis of HIV-related pulmonary hypertension. Ann. NY Acad. Sci.946, 82–94 (2001).
   PubMed Web of Science ®Google Scholar
• Mette SA, Palevsky HI, Pietra GG et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection: a possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am. Rev. Respir. Dis.145, 1196–1200 (1992).
   PubMed Web of Science ®Google Scholar
• Humbert M, Monti G, Fartoukh M et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur. Respir. J.11, 554–559 (1998).
   PubMed Web of Science ®Google Scholar
• Cicalini S, Almodovar S, Grilli E, Flores S. Pulmonary hypertension and HIV infection: epidemiology, pathogenesis, and clinical approach. Clin. Microbiol. Infect. DOI: 10.1111/j.1469–0691.2010.03286.x (2010) (Epub ahead of print).
   Google Scholar
• Marecki JC, Cool CD, Voelkel N, Luciw P, Flores S. Evidence for vascular remodeling in the lungs of macaques infected with simian immunodeficiency virus/HIV NEF recombinant virus. Chest128, 621S–622S (2005).
   PubMed Web of Science ®Google Scholar
• Marecki JC, Cool CD, Parr JE et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-Nef-infected macaques. Am. J. Respir. Crit. Care Med.174, 437–445 (2006).
   PubMed Web of Science ®Google Scholar
• Flores SC, Almodovar S. HIV-1 Nef signature sequences and pulmonary arterial hypertension: structure–function relationships to pathogenesis. FASEB J.23(Meeting Abstract Suppl.), 331.1 (2009).
   Web of Science ®Google Scholar
• Roeth JF, Collins KL. Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol. Mol. Biol. Rev.70, 648–563 (2006).
   Google Scholar
• Sehgal PB, Mukhopadhyay S, Patel K et al. Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-Nef-infected macaques. Am. J. Physiol. Lung Cell. Mol. Physiol.297, L729–L737 (2009).
   PubMed Web of Science ®Google Scholar
• Hassoun PM, Mouthon L, Barberà JA et al. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol.54, S10–S19 (2009).
   PubMed Web of Science ®Google Scholar
• Olivetta E, Percario Z, Fiorucci G et al. HIV-1 Nef induces the release of inflammatory factors from human monocytes/macrophages: involvement of Nef endocytotic signals and NF-κB activation. J. Immunol.170, 1716–1727 (2003).
   PubMed Web of Science ®Google Scholar
• Kim J, Ruff M, Karwatowska-Prokopczuk E et al. HIV envelope protein gp120 induces neuropeptide Y receptor-mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis. Regul. Pept.75–76, 201–205 (1998).
   PubMedGoogle Scholar
• Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem. Biophys. Res. Commun.333, 1107–1115 (2005).
   PubMed Web of Science ®Google Scholar
• Raidel SM, Haase C, Jansen NR et al. Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage. Am. J. Physiol. Heart Circ. Physiol.282, H1672–H1678 (2002).
   PubMed Web of Science ®Google Scholar
• Fiala M, Popik W, Qiao JH et al. HIV-1 induces cardiomyopathy by cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signalling. Cardiovasc. Toxicol.4, 97–107 (2004).
   PubMedGoogle Scholar
• Salvi SS. α1-adrenergic hypothesis for pulmonary hypertension. Chest115, 1708–1719 (1999).
   PubMed Web of Science ®Google Scholar
• Semenza GL. Transcriptional regulation by hypoxia-inducible factor-1: molecular mechanisms of oxygen homeostasis. Trends Cardiovasc. Med.6, 151–157 (1996).
   PubMed Web of Science ®Google Scholar
• Semenza GL. Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. Chest128, 592S–594S (2005).
   PubMed Web of Science ®Google Scholar
• Tipoe GL, Lau TY, Nanji AA, Fung ML. Expression and functions of vasoactive substances regulated by hypoxia-inducible factor-1 in chronic hypoxemia. Cardiovasc. Hematol. Agents Med. Chem.4, 199–218 (2006).
   PubMedGoogle Scholar
• Nakamura K, Fujio H. Are adrenergic receptor blockers effective or contraindicated in pulmonary arterial hypertension? Circ. J.73, 2212–2213 (2009).
   PubMed Web of Science ®Google Scholar
• Provencher S, Herve P, Jais X et al. Deleterious effects of β-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology130, 120–126 (2006).
   PubMed Web of Science ®Google Scholar
• Cool CD, Rai PR, Yeager ME et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N. Engl. J. Med.349, 1113–1122 (2003).
   PubMed Web of Science ®Google Scholar
• Henke-Gendo C, Schulz TF, Hoeper MM. HHV-8 in pulmonary hypertension. N. Engl. J. Med.350, 194–195 (2004).
   PubMed Web of Science ®Google Scholar
• Gutierrez F, Masia M, Padilla S et al. Occult lymphadenopathic Kaposi’s sarcoma associated with severe pulmonary hypertension: a clinical hint about the potential role of HHV-8 in HIV-related pulmonary hypertension? J. Clin. Virol.37, 79–82 (2006).
   PubMed Web of Science ®Google Scholar
• Laney AS, De Marco T, Peters JS et al. Kaposi sarcoma-associated herpesvirus and primary and secondary pulmonary hypertension. Chest127, 762–767 (2005).
   PubMed Web of Science ®Google Scholar
• Katano H, Ito K, Shibuya K, Saji T, Sato Y, Sata T. Lack of human herpesvirus 8 infection in lungs of Japanese patients with primary pulmonary hypertension. J. Infect. Dis.191, 743–745 (2005).
   PubMed Web of Science ®Google Scholar
• Daibata M, Miyoshi I, Taguchi H et al. Absence of human herpesvirus 8 in lung tissues from Japanese patients with primary pulmonary hypertension. Respir. Med.98, 1231–1232 (2004).
   PubMed Web of Science ®Google Scholar
• Bendayan D, Sarid R, Cohen A, Shitrit D, Shechtman I, Kramer MR. Absence of human herpesvirus 8 DNA sequences in lung biopsies from Israeli patients with pulmonary arterial hypertension. Respiration75, 155–157 (2008).
   PubMed Web of Science ®Google Scholar
• Galambos C, Montgomery J, Jenkins FJ. No role for Kaposi Sarcoma-associated herpesvirus in pediatric idiopathic pulmonary hypertension. Pediatr. Pulmonol.41, 122–125 (2006).
   PubMed Web of Science ®Google Scholar
• Nicastri E, Vizza CD, Carletti F et al. Human herpesvirus 8 and pulmonary hypertension. Emerg. Infect. Dis.11, 1480–1482 (2005).
   PubMed Web of Science ®Google Scholar
• Valmary S, Dorfmuller P, Montani D, Humbert M, Brousset P, Degano B. Human γ-herpesviruses EBV and HHV-8 are not detected in the lungs of patients with severe pulmonary arterial hypertension. Chest DOI: 10.1378/chest.10-1200 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Morse JH, Barst RJ, Itescu S et al. Primary pulmonary hypertension in HIV infection. An outcome determined by particular HLA class II alleles. Am. J. Respir. Crit. Care Med.153, 1299–1301 (1996).
   PubMed Web of Science ®Google Scholar
• Sztrymf B, Coulet F, Girerd B et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am. J. Respir. Crit. Care Med.177, 1377–1383 (2008).
   PubMed Web of Science ®Google Scholar
• Caldwell RL, Gadipatti R, Lane KB, Shepherd VL. HIV-1 Tat represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells. J. Leukoc. Biol.79, 192–201 (2006).
   PubMed Web of Science ®Google Scholar
• Degano B, Sitbon O, Simonneau G. Pulmonary arterial hypertension and HIV infection. Semin. Respir. Crit. Care. Med.30, 440–447 (2009).
   PubMed Web of Science ®Google Scholar
• Budhiraja R, Hassoun PM. Portopulmonary hypertension. A tale of two circulations. Chest123, 562–576 (2003).
   PubMed Web of Science ®Google Scholar
• Kuddus RH, Nalesnik MA, Subbotin VM, Rao AS, Gandhi CR. Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes – an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis. J. Hepatol.33, 725–732 (2000).
   PubMed Web of Science ®Google Scholar
• Gandhi CR, Kang Y, De Wolf A et al. Altered endothelin homeostasis in patients undergoing liver transplantation. Liver Transplant. Surg.2, 362–369 (1996).
   PubMedGoogle Scholar
• Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest130, 1657–1663 (2006).
   PubMed Web of Science ®Google Scholar
• Isabelle M, Monteil C, Moritz F et al. Role of α1-adrenoreceptors in cocaine-induced NADPH oxidase expression and cardiac dysfunction. Cardiovasc. Res.67, 699–704 (2005).
   PubMed Web of Science ®Google Scholar
• Abenhaim L, Moride Y, Brenot F et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med.335, 609–616 (1996).
   PubMed Web of Science ®Google Scholar
• Petrache I, Diab K, Knox KS et al. HIV-associated pulmonary emphysema: a review of the literature and inquiry into its mechanism. Thorax63, 463–469 (2008).
   PubMed Web of Science ®Google Scholar
• Galiè N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur. Heart J.30, 2493–2537 (2009).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jais X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation111, 3105–3111 (2005).
   PubMed Web of Science ®Google Scholar
• Confalonieri M, Kodric M, Longo C, Vassallo FG. Bosentan for chronic thromboembolic pulmonary hypertension. Expert Rev. Cardiovasc. Ther.7, 1503–1512 (2009).
   PubMedGoogle Scholar
• Limsukon A, Imran Saeed A, Ramasamy V, Nalamati J, Dhuper S. HIV-related pulmonary hypertension. Mt Sinai J. Med.73, 1037–1044 (2006).
   PubMedGoogle Scholar
• Rich S, Seidlitz M, Osimani D et al. The short-term effects of digoxin in patients with right ventricular dysfunciton from pulmonary hypertension. Chest114, 787–792 (1998).
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med.351, 1425–1436 (2004).
   PubMed Web of Science ®Google Scholar
• Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopatological study of 80 cases. Mayo Clin. Proc.60, 16–25 (1985).
   PubMed Web of Science ®Google Scholar
• Johnson SR, Mehta S, Granton JT. Anticolagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur. Respir. J.28, 999–1004 (2006).
   PubMed Web of Science ®Google Scholar
• Glesby MJ, Aberg JA, Kendall MA et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin. Pharmacol. Ther.78, 143–153 (2005).
   PubMed Web of Science ®Google Scholar
• Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am. J. Respir. Crit. Care Med.162, 1846–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Viale P, Nicastri E et al. Nosocomial bloodstream infections among human immunodeficiency virus-infected patients: incidence and risk factors. Clin. Infect. Dis.34, 677–685 (2002).
   PubMed Web of Science ®Google Scholar
• Cea-Calvo L, Escribano Subías P, Tello de Menesses R et al. Treatment of HIV-associated pulmonary hypertension with treprostinil. Rev. Esp. Cardiol.56, 421–425 (2003).
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Rose F, Schermuly RT. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol.42, 158–164 (2003).
   PubMed Web of Science ®Google Scholar
• Sitbon O, Gressin V, Speich R et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.170, 1212–1217 (2004).
   PubMed Web of Science ®Google Scholar
• Degano B, Yaïci A, Le Pavec J et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur. Resp. J.33, 92–98 (2009).
   PubMed Web of Science ®Google Scholar
• Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J.30, 338–344 (2007).
   PubMed Web of Science ®Google Scholar
• Zacà V, Metra M, Danesi R, Lombardi C, Verzura G, Dei Cas L. Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade. Ther. Adv. Respir. Dis.3, 11–14 (2009).
   PubMedGoogle Scholar
• Galiè N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med.353, 2148–2157 (2005).
   PubMed Web of Science ®Google Scholar
• Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related hypertension. AIDS15, 1747–1748 (2001).
   PubMed Web of Science ®Google Scholar
• Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS16, 1568–1569 (2002).
   PubMed Web of Science ®Google Scholar
• Wong AR, Rascol AH, Abidin NZ, Noor AR, Quan BS. Sildenafil as treatment for human immunodeficiency virus-related pulmonary hypertension in a child. J. Paediatr. Child Health42, 147–148 (2006).
   PubMed Web of Science ®Google Scholar
• Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br. J. Clin. Pharmacol.50, 99–107 (2000).
   PubMed Web of Science ®Google Scholar
• Pellicelli AM, Palmieri F, D’Ambrosio C et al. Role of human immunodeficiency virus in primary pulmonary hypertension. Case reports. Angiology49, 1005–1011 (1998).
   PubMed Web of Science ®Google Scholar
• Cicalini S, Chinello P, Grilli E, Petrosillo N. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. Curr. HIV Res.7, 589–596 (2009).
   PubMed Web of Science ®Google Scholar
• Humbert M. Mediators involved in HIV-related pulmonary arterial hypertension. AIDS22(Suppl. 3), S41–S47 (2008).
   Web of Science ®Google Scholar
• Cicalini S, Chinello P, Petrosillo N, Nicastri E. Pulmonary arterial hypertension in HIV-infected patients. Curr. Hypertens. Rev.4, 131–142 (2008).
   Google Scholar